• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

激素受体阳性和 HER2 阴性乳腺癌且淋巴结受累女性中孤立局部复发的模式和危险因素:PACS 01 和 PACS 04 试验的 10 年随访分析。

Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.

机构信息

Department of Cancer Medicine, University of Paris Saclay, Gustave Roussy, Villejuif, France.

BiostatisticsDepartment, Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France.

出版信息

Breast Cancer Res Treat. 2023 Jun;199(2):371-379. doi: 10.1007/s10549-023-06912-4. Epub 2023 Mar 29.

DOI:10.1007/s10549-023-06912-4
PMID:36988749
Abstract

PURPOSE

We aimed to determine the pattern of isolated local recurrences (ILR) in women with stage II-III hormone receptor-positive and human epidermal growth factor receptor 2 breast cancer (HR + /HER2-BC) after 10-year follow-up.

METHODS

UNICANCER-PACS 01 and PACS 04 trials included 5,008 women with T1-T3 and N1-N3 to evaluate the efficacy of different anthracycline ± taxanes-containing regimens after modified mastectomy or lumpectomy plus axillary lymph node dissection. We analyzed the data from 2,932 women with HR + /HER2- BC to evaluate the cumulative incidence of ILR and describe the factors associated with ILR.

RESULTS

After a median follow-up of 9.1 years (95% CI 9.0-9.2 years), the cumulative incidence of ILR increased steadily between 1 and 10 years from 0.2% to 2.5%. The multivariable analysis showed that older age (subhazard ratios [sHR] = 0.95, 95% CI 0.92-0.99) and mastectomy (sHR = 0.39, 95% CI 0.17-0.86) were associated with lower risk of ILR, and no adjuvant endocrine therapy (sHR = 2.73, 95% CI 1.32 7-5.67) with increased risk of ILR.

CONCLUSION

In this population of high-risk patients with localized HR + /HER2- BC, the risk of ILR was low but remained constant over 10 years. Younger age at diagnosis, breast-conserving surgery, and adjuvant endocrine therapy were independent risk factors of ILR.

摘要

目的

我们旨在确定激素受体阳性和人表皮生长因子受体 2 型乳腺癌(HR+/HER2-BC)女性在 10 年随访后孤立局部复发(ILR)的模式。

方法

UNICANCER-PACS 01 和 PACS 04 试验纳入了 5008 名 T1-T3 和 N1-N3 期患者,旨在评估改良乳房切除术或保乳术加腋窝淋巴结清扫术后不同蒽环类药物±紫杉烷类药物方案的疗效。我们分析了 2932 名 HR+/HER2-BC 女性的数据,以评估 ILR 的累积发生率,并描述与 ILR 相关的因素。

结果

中位随访 9.1 年(95%CI 9.0-9.2 年)后,1-10 年内 ILR 的累积发生率从 0.2%稳步上升至 2.5%。多变量分析显示,年龄较大(亚危险比[sHR] = 0.95,95%CI 0.92-0.99)和乳房切除术(sHR = 0.39,95%CI 0.17-0.86)与 ILR 风险降低相关,而无辅助内分泌治疗(sHR = 2.73,95%CI 1.32-5.67)与 ILR 风险增加相关。

结论

在该局部 HR+/HER2-BC 高危患者人群中,ILR 的风险较低,但在 10 年内保持不变。诊断时年龄较小、保乳手术和辅助内分泌治疗是 ILR 的独立危险因素。

相似文献

1
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.激素受体阳性和 HER2 阴性乳腺癌且淋巴结受累女性中孤立局部复发的模式和危险因素:PACS 01 和 PACS 04 试验的 10 年随访分析。
Breast Cancer Res Treat. 2023 Jun;199(2):371-379. doi: 10.1007/s10549-023-06912-4. Epub 2023 Mar 29.
2
[Local relapse in young (< or = 40 years) women with breast cancer after mastectomy or breast conserving surgery: 15-year results].[40岁及以下年轻女性乳腺癌乳房切除或保乳手术后的局部复发:15年结果]
Magy Onkol. 2005;49(3):203, 205-8. Epub 2005 Oct 25.
3
Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction.腋窝淋巴结清扫术联合即刻淋巴重建的肿瘤安全性。
Breast Cancer Res Treat. 2022 Dec;196(3):657-664. doi: 10.1007/s10549-022-06758-2. Epub 2022 Oct 14.
4
Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.构建的生物学亚型的意义及其与乳房切除术后局部区域复发的关系。
Breast Cancer Res. 2012 May 23;14(3):R82. doi: 10.1186/bcr3197.
5
[Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].[早期浸润性乳腺癌的保乳治疗:局部复发挽救治疗后生存的预后因素]
Magy Onkol. 2007;51(2):127-31. Epub 2007 Jul 29.
6
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31.曲妥珠单抗辅助治疗后 HER2 阳性乳腺癌患者的晚期复发发生率:NCCTG N9831(Alliance)与 NRG 肿瘤学/NSABP B-31 的联合分析
J Clin Oncol. 2019 Dec 10;37(35):3425-3435. doi: 10.1200/JCO.19.00443. Epub 2019 Oct 17.
7
Association Between Regional Nodal Irradiation and Breast Cancer Recurrence-Free Interval for Patients With Low-Risk, Node-Positive Breast Cancer.低危淋巴结阳性乳腺癌患者区域淋巴结放疗与无复发生存期的关系。
Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):861-869. doi: 10.1016/j.ijrobp.2021.10.149. Epub 2021 Nov 8.
8
Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant systemic therapy alone: patterns of recurrence.仅接受辅助性全身治疗的腋窝淋巴结阳性乳腺癌患者的长期随访:复发模式
Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):541-50. doi: 10.1016/s0360-3016(97)00001-1.
9
PREDICTORS OF INFLAMMATORY LOCAL RECURRENCE AFTER BREAST-CONSERVING THERAPY FOR BREAST CANCER: MATCHED CASE-CONTROL STUDY.
J Med Liban. 2015 Oct-Dec;63(4):171-8. doi: 10.12816/0017963.
10
Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.新辅助化疗后 ypN0 和 ypN1-3 腋窝淋巴结阳性女性的保乳术后放疗适应证。
Clin Breast Cancer. 2018 Feb;18(1):e107-e113. doi: 10.1016/j.clbc.2017.07.016. Epub 2017 Aug 1.

本文引用的文献

1
Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor-Positive Breast Cancers.首次同侧激素受体阳性乳腺癌后第二乳腺癌的比较基因组分析。
Clin Cancer Res. 2023 May 1;29(9):1822-1831. doi: 10.1158/1078-0432.CCR-22-2883.
2
Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions.乳腺癌患者内分泌治疗依从性与潜在药物-药物相互作用的关系。
JAMA Netw Open. 2022 Dec 1;5(12):e2244849. doi: 10.1001/jamanetworkopen.2022.44849.
3
Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer.
基因组分析定义了导管原位癌和复发性浸润性乳腺癌的克隆关系。
Nat Genet. 2022 Jun;54(6):850-860. doi: 10.1038/s41588-022-01082-3. Epub 2022 Jun 9.
4
Letter comments on: The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy.关于《保乳治疗后早期乳腺癌患者局部复发对长期预后的影响》的信函评论
Eur J Cancer. 2021 Dec;159:224-226. doi: 10.1016/j.ejca.2021.10.008. Epub 2021 Nov 12.
5
Second invasive breast cancers in patients treated with breast-conserving therapy.保乳治疗后患者的第二侵袭性乳腺癌。
Eur J Surg Oncol. 2021 Oct;47(10):2492-2498. doi: 10.1016/j.ejso.2021.06.013. Epub 2021 Jun 10.
6
Breast tumours maintain a reservoir of subclonal diversity during expansion.乳腺肿瘤在扩增过程中维持亚克隆多样性的储备。
Nature. 2021 Apr;592(7853):302-308. doi: 10.1038/s41586-021-03357-x. Epub 2021 Mar 24.
7
Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.血清检测辅助他莫昔芬治疗不依从与乳腺癌复发风险。
J Clin Oncol. 2020 Aug 20;38(24):2762-2772. doi: 10.1200/JCO.19.01758. Epub 2020 Jun 22.
8
Breast cancer statistics, 2019.乳腺癌统计数据,2019 年。
CA Cancer J Clin. 2019 Nov;69(6):438-451. doi: 10.3322/caac.21583. Epub 2019 Oct 2.
9
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.早期乳腺癌:ESMO 诊断、治疗及随访临床实践指南†
Ann Oncol. 2019 Aug 1;30(8):1194-1220. doi: 10.1093/annonc/mdz173.
10
Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial.CALOR 试验的最终分析:ER 阴性和 ER 阳性孤立区域性局部复发乳腺癌的化疗疗效。
J Clin Oncol. 2018 Apr 10;36(11):1073-1079. doi: 10.1200/JCO.2017.76.5719. Epub 2018 Feb 14.